VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The value of add-on therapy approaches in MF

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the benefits of combining a second agent with a JAK inhibitor when treating patients with myelofibrosis (MF), and further highlights some agents being explored, including navitoclax, pelabresib, and parsaclisib. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter